FDA Inspection 1167083 — Jane L. Rohlf, MD
The FDA completed an inspection of Jane L. Rohlf, MD on Mar 31, 2022 in Trenton, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI)
- End Date
- Mar 31, 2022
- Fiscal Year
- 2022
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Trenton, NJ (United States)
Additional Details
Clinical Investigator (CI)